At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 70 enrolled
Drug / intervention
Exenatide +1 moredrug
Likely dose
Exenatide 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
In Brief
A Phase 4 clinical trial evaluating Exenatide and Placebo for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 70 participants across 1 site.
Detailed Summary
This is a 24-week, randomized, double-blind, placebo-controlled trial of exenatide weekly injection (2mg per dose) as an adjunctive therapy in 70 schizophrenia subjects to examine exenatide's effects on negative symptoms and cognition.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
CollaboratorsStanley Medical Research Institute
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedApr 2015
Primary CompletionJul 2019
Study CompletionJul 2020
TodayJul 2026
First PostedApr 15, 2015
Enrollment StartSep 1, 2014
Primary CompletionJul 1, 2019
Study CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 11.2 years ago
Interventions
Exenatidedrug
Exenatide SQ 2mg/week for 24 weeks.
Placebodrug
Placebo SQ 1x/week for 24 weeks.